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diopathic  pulmonary  ﬁbrosis  (IPF)  is  a  serious,  underdiag-
osed,  chronic  progressive  and  ultimately  fatal  lung  disease.
urvival  is  worse  than  in  many  malignancies.  The  UIP  pat-
ern,  either  on  HRCT  or  biopsy,  is  the  morphologic  hallmark
ut  it  is  not  speciﬁc  for  IPF.  With  two  antiﬁbrotic  drugs  now
vailable  for  treatment  it  is  crucial  to  make  a  precise  diagno-
is  and  differentiate  IPF  from  other  interstitial  lung  diseases
ith  different  prognosis  and  treatment  approaches,  espe-
ially  from  chronic  hypersensitivity  pneumonitis,  idiopathic
brotic  NSIP  and  interstitial  pneumonias  with  autoimmune
eatures.
In  the  past  decade,  signiﬁcant  progress  has  been  made
n  the  ﬁeld  but  many  unresolved  problems  remain.  We  have
earned  that  a  secure  diagnosis  of  a  UIP  pattern  is  possible  by
RCT  criteria  alone  without  the  need  for  histopathological
onﬁrmation.1 It  became  evident  that  diagnostic  security
an  be  increased  by  multidisciplinary  discussion  and  that
ronchoscopic  lung  cryobiopsy  is  probably  equally  informa-
ive  as  surgical  lung  biopsy  in  this  setting.2 Many  patients
re  not  willing  or  are  not  advised  to  undergo  surgical  lung
iopsy  because  it  is  a  risky  procedure  particularly  for  those
ith  severe  disease  and  with  marked  comorbidities.
With  the  advent  of  pharmacological  treatment  options
atients  with  IPF  should  be  diagnosed  quickly.  This  implies
ncreased  awareness  of  the  disease  by  the  general  practi-
ioner  with  the  correct  recognition  of  velcro-like  crackles  on
uscultation  in  the  elderly  and  consecutive  prompt  referal
o  an  expert  center  for  further  studies.  Unfortunately,  the
iagnosis  of  IPF  is  still  frequently  delayed,  as  evidenced  in  a
ecent  interview  of  patient  advocavy  groups  in  9  European
ountries  regarding  the  care  of  IPF  patients.3 The  feedback
egarding  the  diagnosis  of  IPF  showed  that  false  diagnoses
ith  other  respiratory  disorders  are  common,  awareness  of
PF  guidelines  is  often  poor  and  referral  to  specialists  often
igniﬁcantly  delayed.
Based  on  this  background,  the  Portuguese  consensus  doc-
ment  for  the  diagnosis  and  treatment  of  IPF  published  inDOI of original article:
ttp://dx.doi.org/10.1016/j.rppnen.2016.01.003
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173-5115/© 2016 Sociedade Portuguesa de Pneumologia. Published by 
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)his  issue  of  the  Revista  is  a  timely  and  well  balanced  expert
tatement.4 Pneumologists,  radiologists  and  pathologists
laborated  a  concise  paper  aimed  to  alert  the  health  author-
ties  about  the  relevance  of  early  recognition  of  the  disease
nd  the  challenges  with  the  new  drugs  approved,  and  to
ive  practical  advice  how  to  handle  such  a  difﬁcult  disease.
t  is  refreshing  to  see  that  the  authors  avoided  producing
nother  evidence-based  guideline.  The  importance  of  a  mul-
idisciplinary  approach,  including  the  awareness  of  general
ractitioners,  and  experienced  pulmonologists,  radiologists
nd  pathologists  in  the  evaluation  and  correct  treatment
f  diffuse  interstitial  lung  disease,  is  clearly  highlighted.
he  pitfalls  with  the  identiﬁcation  of  a  deﬁnite  UIP  pattern
n  HRCT  are  addressed:  the  distinction  between  honey-
ombing  and  either  traction  bronchiectasis  or  paraseptal
mphysema  can  be  difﬁcult  even  for  an  experienced  radiol-
gist,  as  demonstrated  by  the  high  interobserver  variability
n  the  assessment  of  honeycombing  with  only  moderate
appa  values  of  agreement  ranging  from  0.40  (non-chest
xpert  radiologists)  to  0.58  (expert  chest  radiologists).5
ery  wisely  the  Portuguese  authors  do  not  mention  the  fre-
uent  comorbidity  of  emphysema  in  IPF  patients,  thereby
voiding  any  discussion  on  combined  pulmonary  ﬁbrosis  and
mphysema  (CPFE),6 and  whether  this  is  a distinct  entity,
r  --  what  we  rather  believe  --  the  coincidental  exist-
nce  of  two  diseases  sharing  the  same  risk  factor  cigarette
moking.
In  regard  to  pharmacological  treatment  recommenda-
ions,  the  situation  has  completely  changed  since  the
ublication  of  the  ATS/ERS/JRS/ALAT  2011  guidelines  on
PF1 where  a  rather  nihilistic  view  was  expressed  that
o  proven  therapy  exists  for  this  disease,  and  11  weak
r  strong  negative  recommendations  were  given.  Within
nly  four  years,  in  the  2015  update  of  these  guidelines,7
onditional  recommendations  were  made  for  the  use  of
intedanib  and  for  pirfenidone.  In  this  context,  the  authors
f  the  Portuguese  consensus  document  again  took  a  wise
pproach  by  stating  ﬁrst  that  ‘‘the  therapeutic  strategy
n  IPF  should  be  individualized  for  each  patient,  consid-
ring  the  evaluation  of  potential  beneﬁts  and  risks’’,  and
y  stating  next,  just  descriptively,  that  ‘‘nintedanib  and
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pirfenidone,  two  compounds  with  pleiotropic  mechanisms
of  action  are,  to  date,  the  two  drugs  with  conﬁrmed  efﬁ-
cacy  in  slowing  functional  decline  and  disease  progression
in  IPF  patients’’,  thereby  avoiding  to  grade  the  strength  of
the  recommendation.
On  the  other  hand,  our  Portuguese  colleagues  appear
to  be  quite  strict  with  their  strong  recommendation
that  ‘‘according  to  the  international  recommendations,1,7
asymptomatic  GER  should  be  treated  in  the  majority  of
patients  with  IPF,  namely  with  PPI’’.  This  is  based  on  a  post-
hoc  analysis  of  data  from  three  randomized  controlled  trials
showing  that  IPF  patients  taking  proton  pump  inhibitors  (PPI)
and/or  H2  inhibitors  had  a  signiﬁcantly  slower  decline  in  FVC
over  time.8 In  contrast,  however,  a  recent  post-hoc  anal-
ysis  of  the  placebo  arms  of  three  pirfenidone  trials  (two
CAPACITY  and  ASCEND)  including  624  patients  showed  that
anti-acid  therapy  (mainly  PPIs)  did  not  improve  outcomes  in
patients  with  IPF  and  was  even  associated  with  an  increased
risk  of  infection  in  those  with  more  advanced  disease.9
A  post-hoc  analysis  of  the  INPULSIS  trials  with  nintedanib
showed  similar  ﬁndings  with  no  differences  in  outcomes
between  patients  with  or  without  anti-acid  therapy10 There-
fore,  we  would  currently  recommend  PPI  treatment  only  for
those  IPF  patients  with  symptomatic  GER,  in  agreement  with
the  German  IPF  guideline,11 and  hope  that  this  controver-
sial  issue  will  be  clariﬁed  in  the  future  with  a  prospective
placebo-controlled  PPI  trial  for  IPF.
How  to  handle  IPF?  Many  questions  are  still  open  and
have  not  been  addressed  by  our  Portuguese  colleagues.
These  include  the  question  of  how  to  treat  a  patient  with
probable  or  possible  IPF  compared  to  deﬁnite  IPF,  or  with
unclassiﬁable  IIP.  Should  such  a  patient  ﬁrst  be  treated  with
antiinﬂammatory  therapy?  He  might  have  the  chance  to
respond  if  the  diagnosis  is  not  IPF  but  NSIP.  If  he  would
not  respond,  however,  and  progress  like  IPF,  the  diagnosis
should  be  re-considered  and  changed  into  highly  proba-
ble  IPF.  The  consequence  would  be  to  switch  therapy  to
an  antiﬁbrotic  drug.  This  classiﬁcation  of  IIPs  or  any  ILD
according  to  disease  behaviour  was  newly  introduced  in
the  2013  update  of  the  international  classiﬁcation  of  the
IIPs12 and  seems  to  be  very  relevant  for  patients  with-
out  a  clear  diagnosis  even  after  expert  multidisciplinary
discussion.
Many  open  questions  are  related  to  antiﬁbrotic  therapy,
such  as  when  to  start  and  when  to  stop  treatment,  whether
a  stable  asymptomatic  patient  with  very  mild  disease  should
be  treated,  which  drug  to  use  ﬁrst,  when  to  switch  therapy.
What  achievements  will  we  see  in  the  future?  Will  we  ever
get  evidence  from  controlled  trials  that  combination  ther-
apy  is  better  than  a  single  drug?  Will  gene  polymorphisms  or
other  biomarkers  become  available  which  accurately  predict
the  response  to  a  distinct  antiﬁbrotic  drug?  Much  research  is
needed,  but  we  are  convinced  that  the  landscape  of  IPF  will
change  in  the  near  future  as  rapidly  as  in  the  recent  past,  giv-
ing  ample  opportunities  to  re-write  current  guidelines  and
statements.References
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